Across the U.S., the relaxation of statewide physical distancing measures that are designed to control the COVID-19 pandemic frequently resulted in an immediate reversal of public health gains against SARS-CoV-2, the virus that causes the disease, researchers from Massachusetts General Hospital (MGH) and colleagues reported. Looking at data from all 50 states and the District
An open letter has been published, arguing against lockdown policies and for ‘Focused Protection’. Here are responses of some actual top scientists to the herd immunity declaration from other scientists (many of whom have never published a peer-reviewed paper on Covid-19). Dr Julian Tang, Honorary Associate Professor in Respiratory Sciences, University of Leicester, said: “Having
Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. In this paper, published on EClinicalMedicine are described the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia. 53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU)
Delirium may be one of the presenting symptoms of COVID-19, complicating diagnosis and care of elderly patients with dementia. The autors aim to identify the prevalence and prognostic significance of delirium as the sole onset manifestation of COVID-19 in a retrospective single-centre study based on review of medical charts, conducted during the outbreak peak (March
The contribution of CD4 + T cells to protective or pathogenic immune responses to SARS-CoV-2 infection remains unknown. In this paper it’s presented single-cell transcriptomic analysis of >100,000 viral antigen-reactive CD4 + T cells from 40 COVID-19 patients. In hospitalized patients compared to non-hospitalized patients, were found increased proportions of cytotoxic follicular helper (T FH
The more common manifestation in the COVID-19 era may be HFpEF related primarily to the unmasking of subclinical HFpEF and secondarily to the development of new HFpEF following infection with SARS-CoV-2. Patients with preexisting cardiovascular disease (CVD) who develop coronavirus disease 2019 (COVID-19) have worse outcomes than patients without CVD.Infection with severe acute respiratory syndrome
Fewer than 10 percent of the U.S. adult population formed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the pandemic, according to a study published online Sept. 25 in The Lancet. Shuchi Anand, M.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a cross-sectional
In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. Despite promising early reports and strong in vitro performance, Hydroxychloroquine (HCQ) has become the major therapeutic disappointment of the COVID pandemic. Research
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China and caused a coronavirus disease 2019 (COVID-19) pandemic. To mitigate the public health, economic and societal impacts of the virus, a vaccine is urgently needed. The development of SARS-CoV-2 vaccines was initiated in early January 2020 when the sequence of the virus
Here is reported the content of the Correspondence We read with great interest the results presented by Denis Logunov andcolleagues on the safety and efficacy of a Russian vaccine for COVID-19. Although the study results are potentially significant, we have severalconcerns, which, due to the accelerated distribution of the vaccine to thepopulation, we described in
